ASH 2023

• CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study

Eric Durot

• Validation of POD24 as a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials

Clémentine Sarkozy

• Tazemetostat in Combination with RCHOP in Patients with high-risk, frontline Follicular Lymphoma (Epi-RCHOP): a phase II study from the LYSA

Loic Ysebaert

• Efficacy of Chimeric Antigen Receptor T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Gloria Iacoboni

• Real-Word experience of CAR T-cells in Patients with Relapsed/Refractory Follicular Lymphoma : a DESCART Registry Analysis From the LYSA

Loic Ysebaert

• Results of the EpiRCHOP phase II study, evaluating the efficacy of tazemetostat in combination with R-CHOP in elderly newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a LYSA Study

Clémentine Sarkozy

• R-GemOx Plus Nivolumab Vs R-GemOx As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Interim Analysis of the Niveau Trial, an International, Randomized Phase 3 Study of the AGMT, GLA, HOVON, Lysa and PLRG

Gehrard Held

• Single Cell Longitudinal Characterization of FL heterogeneity and residual disease in the Bone Marrow from low-tumor burden FL enrolled in the FLIRT clinical trial

Alicia Beyou

• Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary LYSA Study

Alexis Claudel

• Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Pierre Sesques

• Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials

Clémentine Sarkozy

• Synthetic Control Arm from Clinical Trialsand Real-World Data from Lysa Group forUntreated Diffuse Large B Cell LymphomaPatients Aged over 80 Years: A Bona Fide strategy for Innovative Clinical Trial

Valentin Letailleur

• Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

Vincent Ribrag

• Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Stefan K. Alig

• CD20low/CD68high a Promising Microenvironnement Profile Identifying Classical Hos=dgkin Lymphoma Patients with Poor Outcome a LYSA Study

Alexandra Taverse-Glehen

• Very Elderly Rituximab Associated to Lenalidomide – Tafasitamab Combination in Frontline DLBCL Patients”, a Phase II Open-Label Study Evaluating Efficacy of Lenalinomide and Tafasitamab Combination Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older from the Lysa Group

Benoit Tessoulin

• First Line Therapy Evaluation Using Propensity Score Approach in Newly Diagnosed Advanced Classical Hodgkin Lymphoma Patients from Prospective Real-World Realysa Cohort and Phase 3 AHL2011 Trial

Cédric Rossi

• Real World Data of Axicabtagene CiloleucelAs Second Line Therapy for Patients withLarge B Cell Lymphoma: First Results of aLysa Study from the French DESCAR-T registry

Gabriel Brisou

• Marsun, a Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL)

Catherine Thieblemont

• Outcomes of High-Grade B-cell Lymphoma (HGBL-DH, TH, NOS) as compared to other LBCL subtypes in patients treated with CD19-Directed CAR-T cells at 3rd line or more. A LYSA study based on the French DESCAR-T Registry.

Xavier Phina-Ziebin

• Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia : A GRAALL study from the DESCAR-T registry

F. Rabian

• Invasive fungal infections after CAR T-cell therapy for B-cell lymphoma: a study from the French DESCART registry

Amélie Bouvier

• French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Sarah Cayla

• Low TMTV InBuences Response and Outcomes in R/R DLBCL 3L+ Patients Treated with CAR-T Cells : First Results of FDG-PET/CT Analysis in the French Descar-T Registry

Yassine Al-Tabaa

• Tislelizumab, an Anti-PD1 Antibody, in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma in Tirhol Bgb-A317-210: A Prospective Multicenter Lysa Phase 2 Study Conducted in Western Countries

Hervé Ghesquieres

• Impact of Brentuximab Vedotin in Patients with Breast Implant–Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

David Sibon

• Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

Cédric Rossi